| Literature DB >> 26209436 |
Hesha J Duggirala1, Joseph M Tonning2, Ella Smith3, Roselie A Bright4, John D Baker5, Robert Ball6, Carlos Bell2, Susan J Bright-Ponte5, Taxiarchis Botsis6, Khaled Bouri4, Marc Boyer3, Keith Burkhart2, G Steven Condrey7, James J Chen8, Stuart Chirtel3, Ross W Filice4, Henry Francis2, Hongying Jiang9, Jonathan Levine4, David Martin6, Taiye Oladipo3, Rene O'Neill9, Lee Anne M Palmer5, Antonio Paredes10, George Rochester10, Deborah Sholtes10, Ana Szarfman2, Hui-Lee Wong9, Zhiheng Xu9, Taha Kass-Hout4.
Abstract
OBJECTIVES: This article summarizes past and current data mining activities at the United States Food and Drug Administration (FDA). TARGET AUDIENCE: We address data miners in all sectors, anyone interested in the safety of products regulated by the FDA (predominantly medical products, food, veterinary products and nutrition, and tobacco products), and those interested in FDA activities. SCOPE: Topics include routine and developmental data mining activities, short descriptions of mined FDA data, advantages and challenges of data mining at the FDA, and future directions of data mining at the FDA. Published by Oxford University Press on behalf of the American Medical Informatics Association 2015. This work is written by US Government employees and is in the public domain in the US.Entities:
Keywords: data mining; disproportionality analysis; pharmacovigilance
Mesh:
Year: 2015 PMID: 26209436 DOI: 10.1093/jamia/ocv063
Source DB: PubMed Journal: J Am Med Inform Assoc ISSN: 1067-5027 Impact factor: 4.497